IceCure: 3 Key Takeaways for Long-Term Investors
The clinical timeline is slipping as partner site contracts move slowly, putting the 400-patient ChoICE target at risk for investors weighing growth against losses.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.